Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMI-115 in male androgenetic alopecia
CTR20261971Phase 2Active
- Sponsor
- HopeMed
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of HMI-115 in androgenetic alopecia (AGA) (4 arms), sponsored by HopeMed. Primary endpoint: Change from baseline in non-vellus hair count within the target area. Started Jun 2026; status: active.
02
Drugs
HMI-115
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on CTR20261971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261971.